Scilex Holding (NASDAQ:SCLX – Get Free Report) insider Jaisim Shah acquired 32,000 shares of the stock in a transaction on Tuesday, October 29th. The stock was bought at an average price of $0.99 per share, for a total transaction of $31,680.00. Following the transaction, the insider now owns 109,333 shares in the company, valued at approximately $108,239.67. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Jaisim Shah also recently made the following trade(s):
- On Wednesday, October 16th, Jaisim Shah bought 30,000 shares of Scilex stock. The shares were purchased at an average cost of $0.99 per share, with a total value of $29,700.00.
Scilex Stock Performance
NASDAQ:SCLX opened at $0.94 on Thursday. The stock has a market capitalization of $180.63 million, a PE ratio of -0.66 and a beta of 1.15. Scilex Holding has a fifty-two week low of $0.73 and a fifty-two week high of $2.63. The company has a fifty day moving average of $0.98 and a two-hundred day moving average of $1.22.
Institutional Trading of Scilex
A number of hedge funds have recently bought and sold shares of SCLX. Armistice Capital LLC acquired a new position in Scilex during the second quarter worth $23,064,000. Vanguard Group Inc. raised its holdings in shares of Scilex by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 3,988,265 shares of the company’s stock worth $6,341,000 after acquiring an additional 55,757 shares during the period. Donald L. Hagan LLC boosted its position in shares of Scilex by 15.4% during the 3rd quarter. Donald L. Hagan LLC now owns 130,792 shares of the company’s stock valued at $121,000 after acquiring an additional 17,500 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Scilex by 321.4% in the second quarter. XTX Topco Ltd now owns 105,431 shares of the company’s stock valued at $203,000 after purchasing an additional 80,409 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in Scilex during the second quarter worth about $31,000. Institutional investors and hedge funds own 69.67% of the company’s stock.
Wall Street Analyst Weigh In
Several analysts recently commented on SCLX shares. Alliance Global Partners began coverage on shares of Scilex in a research report on Wednesday, October 16th. They set a “buy” rating and a $14.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Scilex in a research note on Monday, October 21st.
Check Out Our Latest Analysis on Scilex
About Scilex
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Recommended Stories
- Five stocks we like better than Scilex
- Short Selling: How to Short a Stock
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What is the NASDAQ Stock Exchange?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.